Gonadorelin monograph

Gonadorelin

Overview

Gonadorelin is the human hypothalamic gonadotropin-releasing hormone (GnRH), a decapeptide that triggers pituitary release of LH and FSH. In practice, it is used mainly as a diagnostic agent and historically in fertility-related contexts; it is not a mainstream bodybuilding drug, and performance-use claims are not well established. The evidence base for human pharmacokinetics is limited because the native peptide is rapidly cleared and short-acting.

Pharmacokinetics & Mechanism

• Class: Endogenous decapeptide hypothalamic hormone; GnRH agonist used diagnostically and in limited clinical settings
• Mechanism of action: Binds GnRH receptors on anterior pituitary gonadotrophs, activating the Gq/11-phospholipase C pathway, increasing intracellular calcium and stimulating pulsatile luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release. Continuous exposure can desensitize/downregulate the receptor and suppress gonadotropin output, but that is a feature of GnRH agonist therapy generally, not a performance-enhancement effect that is established for gonadorelin use.
• Target(s): GnRH receptor (GNRHR) on pituitary gonadotrophs; downstream LH/FSH secretion axis of the hypothalamic-pituitary-gonadal (HPG) pathway.
• Route(s) of administration: Primarily subcutaneous or intravenous injection in clinical/research use; not orally bioavailable. The DailyMed listing found is for CYSTORELIN, a veterinary gonadorelin product.
• Onset: Rapid, typically within minutes to tens of minutes for pituitary LH/FSH response after parenteral administration; exact onset depends on assay timing and dose. Not well established for bodybuilding use.
• Half-life: Very short plasma half-life in humans, generally reported in the range of only a few minutes; exact value varies by source and assay conditions. I did not find a high-quality FDA human label for gonadorelin itself in this search; available evidence supports that native GnRH is rapidly cleared rather than having a depot-like half-life. DAC/extended-release variants are not gonadorelin itself and should not be conflated with native gonadorelin.
• Metabolism / clearance: Cleared rapidly by enzymatic degradation (peptidases) and hepatic/renal handling typical of small peptides; not orally stable. Human clearance is fast enough that pulsatile physiologic secretion matters more than any single dose. Detailed human clearance numbers are not well established in the sources found here.